Division of Nephrology University of Texas Southwestern Medical Center Dallas TX.
Division of Cardiology Tufts Medical Center Boston MA.
J Am Heart Assoc. 2023 Feb 7;12(3):e025993. doi: 10.1161/JAHA.122.025993. Epub 2023 Feb 3.
Background Advanced kidney disease is often a relative contraindication to left ventricular assist device (LVAD) implantation because of concerns for poor outcomes including worsening kidney disease. Data are lacking on long-term changes and sex-based differences in estimated glomerular filtration rate (eGFR), with published data limited by potential bias introduced by the competing risks of death and heart transplantation. Methods and Results We conducted a longitudinal analysis of 288 adults receiving durable continuous-flow LVADs from January 2010 to December 2017 at a single center. A joint model was constructed to evaluate change in eGFR over 2 years, the prespecified primary outcome, adjusted for the competing risks of death and heart transplantation. Median baseline eGFR was 60 mL/min per 1.73 m (interquartile range 42-78). At 2 years, 74 patients died and 104 received a heart transplant. In unadjusted analysis, LVAD recipients had a modest initial increase in eGFR of ≈2 mL/min per 1.73 m within the first 6 months after implantation, followed by a decrease in eGFR below baseline values at 1 and 2 years. Men experienced an eGFR decline of 5 to 10 mL/min per 1.73 m over the first year which then stabilized, while women had an ≈5 mL/min per 1.73 m increase in eGFR within the first 6 months followed by decline towards baseline eGFR levels (interaction =0.005). Conclusions Estimated GFR remains relatively stable in most patients following LVAD implantation. Larger studies are needed to investigate sex-based differences in eGFR and to evaluate eGFR trajectory and mortality in LVAD recipients with lower eGFR.
由于担心包括肾功能恶化在内的不良结局,晚期肾病通常是左心室辅助装置(LVAD)植入的相对禁忌证。关于估计肾小球滤过率(eGFR)的长期变化和基于性别的差异的数据缺乏,发表的数据受到死亡和心脏移植竞争风险引入的潜在偏倚的限制。
我们对 2010 年 1 月至 2017 年 12 月在单中心接受耐用连续血流 LVAD 的 288 例成人进行了纵向分析。构建了一个联合模型,以评估 2 年内 eGFR 的变化,这是预先规定的主要结局,调整了死亡和心脏移植的竞争风险。中位基线 eGFR 为 60mL/min/1.73m(四分位距 42-78)。在 2 年内,74 例患者死亡,104 例患者接受心脏移植。在未调整的分析中,LVAD 受者在植入后最初的 6 个月内 eGFR 有适度的初始增加,约为 2mL/min/1.73m,随后在 1 年和 2 年时 eGFR 低于基线值。男性在第 1 年内 eGFR 下降 5 至 10mL/min/1.73m,然后稳定,而女性在最初的 6 个月内 eGFR 增加约 5mL/min/1.73m,然后下降至基线 eGFR 水平(交互作用=0.005)。
在大多数接受 LVAD 植入的患者中,eGFR 相对稳定。需要更大的研究来研究 eGFR 方面的性别差异,并评估 eGFR 轨迹和 eGFR 较低的 LVAD 受者的死亡率。